AU2020248438A1 - Compositions and methods for treating ocular disease - Google Patents

Compositions and methods for treating ocular disease Download PDF

Info

Publication number
AU2020248438A1
AU2020248438A1 AU2020248438A AU2020248438A AU2020248438A1 AU 2020248438 A1 AU2020248438 A1 AU 2020248438A1 AU 2020248438 A AU2020248438 A AU 2020248438A AU 2020248438 A AU2020248438 A AU 2020248438A AU 2020248438 A1 AU2020248438 A1 AU 2020248438A1
Authority
AU
Australia
Prior art keywords
seq
peptide
unit dose
salt
abu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020248438A
Other languages
English (en)
Inventor
Niranjan B. Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asclepix Therapeutics Inc
Original Assignee
Asclepix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asclepix Therapeutics Inc filed Critical Asclepix Therapeutics Inc
Publication of AU2020248438A1 publication Critical patent/AU2020248438A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2020248438A 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease Pending AU2020248438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
US62/824,017 2019-03-26
PCT/US2020/024972 WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Publications (1)

Publication Number Publication Date
AU2020248438A1 true AU2020248438A1 (en) 2021-10-28

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020248438A Pending AU2020248438A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Country Status (12)

Country Link
US (1) US12540171B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946418A4 (cg-RX-API-DMAC7.html)
JP (1) JP7650074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210146352A (cg-RX-API-DMAC7.html)
CN (1) CN113710264A (cg-RX-API-DMAC7.html)
AU (1) AU2020248438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3134816A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192607A1 (cg-RX-API-DMAC7.html)
IL (1) IL286625A (cg-RX-API-DMAC7.html)
MX (1) MX2021011727A (cg-RX-API-DMAC7.html)
WO (1) WO2020198481A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107235B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
EP2649095B1 (en) * 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
CN108883150A (zh) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
US20200179285A1 (en) * 2017-05-08 2020-06-11 The Johns Hopkins University Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR

Also Published As

Publication number Publication date
KR20210146352A (ko) 2021-12-03
ZA202107235B (en) 2023-10-25
WO2020198481A1 (en) 2020-10-01
CA3134816A1 (en) 2020-10-01
EP3946418A4 (en) 2023-02-22
US12540171B2 (en) 2026-02-03
JP7650074B2 (ja) 2025-03-24
EA202192607A1 (ru) 2022-03-03
US20230054032A1 (en) 2023-02-23
CN113710264A (zh) 2021-11-26
IL286625A (en) 2021-12-01
MX2021011727A (es) 2022-01-24
JP2022527276A (ja) 2022-06-01
EP3946418A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
AU2016241499B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CN109715189B (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
ES3041647T3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
ES2886542T3 (es) Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente
US12540171B2 (en) Compositions and methods for treating ocular disease
AU2025203373A1 (en) Application Of Fusion Protein In Treating Age-Related Macular Degeneration
TW201904610A (zh) 用於治療新生血管型青光眼之非抗體vegf拮抗劑
KR20220062279A (ko) 안질환의 치료 방법
EP4251204A1 (en) Vegf antagonist for use in methods for treating ocular diseases
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
WO2026036282A1 (en) Multispecific fusion proteins targeting angiogenic factors
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
AU2024272228A1 (en) Annexin a5 protein as a combination therapy with an anti-vegf agent for use in the treatment of macular oedema or retinal vein occlusion